Top Markets
Coin of the day
Metagenomi, Inc. Common Stock Metagenomi, Inc. Common Stock

Metagenomi, Inc. Common Stock

MGX
Rankning i aktier #25865
Metagenomi, Inc. operates as a biotechnology company focused on gene editing,... Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Aktiekurs
$1.21
Senast synkroniserad: 2026-08-20
Marknadsvärde
$45.55M
Förändring (1 dag)
-2.43%
Förändring (1 år)
-34.60%
Land
US
Handel Metagenomi, Inc. Common Stock (MGX)

Kategori

P/B-tal för Metagenomi, Inc. Common Stock (MGX)
P/B-tal per 2026 TTM: 0
Enligt Metagenomi, Inc. Common Stock senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för Metagenomi, Inc. Common Stock från 2026 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
Inte tillräckligt med data för de angivna datumen.
P/B-tal för liknande företag eller konkurrenter
Företag P/B-tal Skillnad i P/B-tal Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
3.7087 -
US